When Daniel K. Conners began thinking about starting a small biotechnology company in the basement of his Minnesota home during the mid 1990s, he could not have imagined that this company might one day change how cancer is treated around the world.

Twelve years later, the biotech company that Conners envisioned is developing a targeted immunotherapy drug that works synergistically with monoclonal antibodies to engage innate immune cells to kill cancer. This entirely new cancer treatment is still being tested in the clinic, but the preliminary results are attracting interest from leading oncologists and pharmaceutical companies.

Excited about the possibility of the technology to significantly advance the outcomes for cancer patients, researchers such as Daniel K Conners feel that Biothera is on the forefront of carbohydrate biotechnology and its relevance for a cancer cure.

Led by Daniel K Conners, Biothera is not only creating cancer drugs, has developed on the same technology platform an immune health component. Currently Biothera manufactures and markets non-pharmaceutical (food-grade) elements for beverages, dietary supplements, cosmetics and animal nutrition. With an increasing industry and tremendous increases in sales of immune-enhancing technologies Biothera expects large revenues as it captures market share.

Headquartered in Eagan, Minnesota USA, Biotheras patents and patents pending span the globe, with intellectual property rights including more than 40 U.S., plus patent filings in more than 20 other countries. Biothera has 25 scientists alone focused on research and development. Biothera expects to grow its technology platform significantly.

Biopolymer Engineering, Inc was founded by Daniel K Conners in 1997 and later renamed Biothera. Biothera now focuses on the manufacturing and improvement of innate complex carbohydrates. Bioploymer Engineering was recognized as a principal in the purification, characterization and production of a variety of carbohydrates. However, Biotheras platform technology carbohydrate predates the company.

According to Conners, researchers at various universities for decades have studied certain carbohydrates in fungi, cereals and bacteria and have identified a link between these polysaccharides and immune activity. But prior to Biothera, no one had successfully delineated the specific mechanism of action these carbohydrates use to effect immune function.